Clinical trial
FemBloc® Permanent Contraception - Early Pivotal Trial
NCT03433911 · Femasys Inc., Industry · Active, not recruiting
Key facts
| NCT number | NCT03433911 |
|---|---|
| Title | FemBloc® Permanent Contraception - Early Pivotal Trial |
| Official title | BLOC: Prospective Multi-Center Office Based Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception |
| Acronym | BLOC |
| Lead sponsor | Femasys Inc., Industry |
| Status | Active, not recruiting |
| Study type | Interventional |
| Conditions | Contraception |
| Intervention type | Device, Procedure |
| Interventions | FemBloc, Laparoscopic bilateral tubal sterilization |
| Enrollment | 240 |
| Start date | Feb 2, 2018 |
| Primary completion | Jan 31, 2020 |
| Completion | Jul 1, 2025 |
| First posted | Feb 15, 2018 |
| Last update posted | Jan 27, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: